Crispr Therapeutics AG (NASDAQ:CRSP) – Analysts at Oppenheimer increased their FY2019 earnings per share estimates for Crispr Therapeutics in a research note issued to investors on Monday, November 25th, Zacks Investment Research reports. Oppenheimer analyst S. Tuerkcan now anticipates that the company will post earnings of $0.59 per share for the year, up from their previous estimate of $0.58. Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock.
Other equities analysts have also recently issued research reports about the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Chardan Capital reiterated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Finally, BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $69.54.
NASDAQ CRSP traded up $0.38 during trading on Wednesday, hitting $66.03. 1,136,382 shares of the stock traded hands, compared to its average volume of 712,154. The company has a market capitalization of $3.72 billion, a P/E ratio of -19.19 and a beta of 3.31. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $58.41 and a 200-day simple moving average of $48.30. Crispr Therapeutics has a 12-month low of $22.22 and a 12-month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Benjamin Edwards Inc. boosted its holdings in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares in the last quarter. Traynor Capital Management Inc. raised its position in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after purchasing an additional 375 shares in the last quarter. Commonwealth Equity Services LLC raised its position in Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after purchasing an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in Crispr Therapeutics by 7.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after purchasing an additional 467 shares in the last quarter. Institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is the Federal Reserve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.